Company intelligence / Profile preview

BioPromin

San Rafael, California, United States

Ownership: Private
Development stage: Other

Overview

BioMarin has six approved orphan drugs for rare genetic diseases including lysosomal storage disorders and hemophilia A, with additional pipeline programs in development.[1][2]

Therapeutic areas: HematologyNeurologyRare DiseasesMetabolic Disorders
Modalities: Enzyme replacement therapyRecombinant proteinSmall moleculeGene therapy
Industry: Biotech

Partnerships

Genzyme (for Aldurazyme commercialization)

Beyond the preview

Go deeper on BioPromin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPromin.

Explore the full profile